Scott Rowley, MD, the Chief of John Theurer Cancer Center’s Blood and Marrow Stem Cell Transplantation Division, discusses the challenges of allogeneic stem cell transplant.

Many allogeneic transplant candidates have resistant disease or comorbiditiesâ€‹ due to previous treatments. This has resulted in a push for creating reduced or less toxic regimens.

The biggest challenge in allogeneic transplant is post-transplant relapse. A primary area of focus in the transplant community is to find novel agents or regimens to reduce risk of relapse, says Rowley. 

Videos

Scott Rowley, MD, the Chief of John Theurer Cancer Center's Blood and Marrow Stem Cell Transplantation Division, discusses the challenges of allogeneic stem cell transplant.

Scott Rowley, MD

Articles

Dr. Scott Rowley on Allogeneic Stem Cell Transplant